Alembic Q3 net up 7% at Rs 71 cr

Net sales during the period under review stood at Rs 514.9 crore

Press Trust of India New Delhi
Last Updated : Feb 04 2015 | 4:21 PM IST
Alembic Pharmaceuticals today reported 7.17 per cent increase in net profit at Rs 70.66 crore for the third quarter ended December 31, 2014-15.

It had posted net profit of Rs 65.93 crore in the same quarter of the 2013-14 fiscal, Alembic Pharma said in a filing to the BSE.

Net sales during the period under review stood at Rs 514.9 crore as against Rs 486.74 crore in the year-ago quarter, the company said.

Also Read

Branded formulations business in India posted sales of Rs 250 crore as against Rs 225.1 crore, up 11 per cent, while speciality and acute segments grew by 19 per cent and 3 per cent respectively, it added.

International generic formulation posted a growth of 3 per cent at Rs 133.3 crore as compared to Rs 129.6 crore a year-ago.

During the quarter, the company filed one abbreviated new drug application (ANDAs) and received approval for one. It also filed two drug master file (DMF) applications during the period.

Alembic Pharmaceuticals stock closed over 11 per cent down at Rs 429.55 apiece on the BSE.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 04 2015 | 3:50 PM IST

Next Story